Trials
2 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Form: solution for injection; Route of Administration: IVT injection”In the company’s words, NCT06510816 on ClinicalTrials.gov
- Tested for
- Geographic Atrophy (2 trials)
- Main trialPhase 3
- “The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with dry AMD with GA.”In the company’s words, NCT06510816 on ClinicalTrials.gov
- Other names
- ANX007
Other drugs for Geographic Atrophy
- TinlarebantBelite Bio, Inc · Phase 3
- CemdisiranRegeneron · Phase 3
- PozelimabRegeneron · Phase 3
- BevemipretideMighty Therapeutics Inc. · Phase 2/3
- JNJ-81201887Johnson & Johnson (Janssen) · Phase 2/3
- BI 1584862Boehringer Ingelheim · Phase 2
Coming up2
- 31 Jul 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 31 Jul 2027 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | |
| Phase 3Not yet recruiting | 31 Jul 2029 | An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | |
| Phase 2Completed | 28 Mar 2023 | A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026